Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Allogenic gamma delta T cells therapy - Beroni Group

Next Previous
X
Search
Drug Profile

Allogenic gamma delta T cells therapy - Beroni Group

Alternative Names: Allogeneic gamma delta T cell anti-cancer therapy; Allogenic γδ T cell - Beroni Group; γδ T cell therapies

Latest Information Update: 28 Mar 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Beroni Group
  • Class Antineoplastics; Immunotherapies; T lymphocyte cell therapies
  • Mechanism of Action T lymphocyte replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • No development reported Solid tumours

Most Recent Events

  • 28 Mar 2024 No recent reports of development identified for preclinical development in Solid-tumours in Australia (Parenteral)
  • 02 Jun 2021 Allogenic gamma delta T cells therapy is available for licensing as of 02 Jun 2021. https://www.beronigroup.com/anti-cancer-drugs/
  • 28 May 2021 Beroni Group enters Memorandum of Understanding with Tella for cancer treatment

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top